Attenuated influenza virions expressing the SARS-CoV-2 receptor-binding domain induce neutralizing antibodies in mice
Preprint
Abstract
An effective vaccine is essential to controlling the spread of SARS-CoV-2 virus. Here, we describe an influenza-virus-based vaccine for SARS-CoV-2. We incorporated a membrane-anchored form of the SARS-CoV-2 Spike receptor binding domain (RBD) in place of the neuraminidase (NA) coding sequence in an influenza virus also possessing a mutation that reduces the affinity of hemagglutinin for its sialic acid receptor. The resulting ΔNA(RBD)-Flu virus can be generated by reverse genetics and grown to high titers in cell culture. A single-dose intranasal inoculation of mice with ΔNA(RBD)-Flu elicits serum neutralizing antibody titers against SAR-CoV-2 comparable to those observed in humans following natural infection (∼1:200). Furthermore, ΔNA(RBD)-Flu itself causes no apparent disease in mice. It might be possible to produce a vaccine similar to ΔNA(RBD)-Flu at scale by leveraging existing platforms for production of influenza vaccines.Keywords
All Related Versions
- Published version: Viruses, 12 (9), 987.
This publication has 52 references indexed in Scilit:
- The B7-1 Cytoplasmic Tail Enhances Intracellular Transport and Mammalian Cell Surface Display of Chimeric Proteins in the Absence of a Linear ER Export MotifPLOS ONE, 2013
- A Recombinant Influenza A Virus Expressing Domain III of West Nile Virus Induces Protective Immune Responses against Influenza and West Nile VirusPLOS ONE, 2011
- Rewiring the RNAs of influenza virus to prevent reassortmentProceedings of the National Academy of Sciences, 2009
- Infectivity Studies of Influenza Virus Hemagglutinin Receptor Binding Site Mutants in MiceJournal of Virology, 2008
- Attachment of infectious influenza A viruses of various subtypes to live mammalian and avian cells as measured by flow cytometryVirus Research, 2007
- Chimeric Influenza Virus Hemagglutinin Proteins Containing Large Domains of the Bacillus anthracis Protective Antigen: Protein Characterization, Incorporation into Infectious Influenza Viruses, and AntigenicityJournal of Virology, 2005
- Protection afforded by intranasal immunization with the neuraminidase-lacking mutant of influenza A virus in a ferret modelVaccine, 2005
- Characterization of a Neuraminidase-Deficient Influenza A Virus as a Potential Gene Delivery Vector and a Live VaccineJournal of Virology, 2004
- Comparison of in vitro immunostimulatory potential of live and inactivated influenza virusesHuman Immunology, 2000
- A DNA transfection system for generation of influenza A virus from eight plasmidsProceedings of the National Academy of Sciences of the United States of America, 2000